Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Tobacco smoking is implicated in psoriasis among adults.
To determine whether prenatal, infantile, and childhood tobacco exposure increase risk of pediatric psoriasis.
Data from Danish National Birth Cohort participants were collected at approximately gestational week 12 and when the children were approximately 6 months and 11 years of age. In total, 25 812 offspring with complete data from the Danish National Birth Cohort were included. We estimated the odds of pediatric psoriasis with tobacco exposure prenatally, from birth to age 6 months (early infancy), and at age 11 years (childhood).
We observed an increased risk of pediatric psoriasis among offspring with prenatal tobacco exposure (adjusted odds ratio [OR], 1.39; 95% confidence interval [CI], 1.06-1.82). An exposure-response relationship was observed for increasing quantities of cigarettes smoked daily (≥16 cigarettes: adjusted OR, 2.92; 95% CI, 1.20-7.10; P for trend = .038). The associations with infantile (adjusted OR, 1.17; 95% CI, 0.76-1.79) and childhood (adjusted OR, 1.10; 95% CI, 0.77-1.58) tobacco exposure were attenuated after controlling for prenatal exposure.
Outcome status was maternally reported.
Prenatal tobacco exposure may increase the risk of pediatric psoriasis in a monotonic fashion, indicating that smoking may play a causal role in psoriasis pathogenesis.Le texte complet de cet article est disponible en PDF.
Key words : cohort, dermatology, epidemiology, pediatric psoriasis, psoriasis, public health, smoking, tobacco
Abbreviations used : CI, DNBC, GW, NRT, OR
| Funding sources: Supported by a grant from the LEO Foundation and the Danish Dermatological Society. The LEO Foundation and the Danish Dermatological Society were not involved in any portion of the study design, data collection, data analysis, manuscript preparation, or review process, or in the decision to submit the manuscript for publication.
| Disclosure: Dr Skov has been a paid speaker for AbbVie, Eli Lilly, Novartis, and LEO Pharma; has been a consultant or has served on advisory boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, UCB, Almirall, and Sanofi; has served as an investigator for AbbVie, Janssen Cilag, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novartis, Regeneron, and LEO Pharma; and has received research and educational grants from Pfizer, AbbVie, Novartis, Sanofi, Janssen Cilag, and LEO Pharma. MScPH Groot and Drs Nybo Andersen, Blegvad, and Pinot de Moira have no conflicts of interest to declare.
| IRB approval status: Approved by the Danish Data Protection Agency through the joint notification of the Faculty of Health and Medical Sciences at the University of Copenhagen (Sund-2017-09).
| Reprints not available from the authors.